AdAlta : Presentation to Share Cafe Webinar
1AD.AX
For personal use only
20 January 2022
ASX Announcement
ADALTA UPDATED CORPORATE PRESENTATION AND INVESTOR WEBINAR
MELBOURNE Australia, 20 January 2022: AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform is pleased to announce its participation in the ShareCafe Small Cap "Hidden Gems" Webinar, to be held on Friday 21 January 2022 from 12:30pm AEDT / 9:30am AWST.
Through the session, CEO and Managing Director, Dr Tim Oldham will provide an overview of progress on the company's programs in the areas of fibrosis/inflammation and oncology; discuss the recent data read out on the nebulised version of AD-214, as well as plans for the year ahead.
This webinar is able to be viewed live via Zoom. To access further details of the event, please copy and paste the following link into your internet browser:
https://us02web.zoom.us/webinar/register/5416151767246/WN_vGZ5UY_pRcWUx2OlF RG9QQ
The investor presentation to be delivered during the webinar is attached. A recorded copy of the webinar will be made available via AdAlta's website at www.adalta.com.aufollowing the event.
Authorised for lodgement by:
Tim Oldham
CEO and Managing Director
January 2022
Notes to Editors
About AdAlta
AdAlta Limited (ASX:1AD) is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to generate a promising new class of medicines with the potential to treat some of today's most challenging diseases.
The Company's lead asset, called AD-214, is a first-in-class product being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases and potentially cancers, for which current therapies are sub-optimal and there is a high unmet medical need. AD-214 has progressed through Phase I clinical trials in healthy volunteers.
For personal use only
AdAlta is also entering collaborative partnerships to co-developi-body enabled therapeutics. The Company has a revenue generating partnership agreement with GE Healthcare which is designed to discover a diagnostic imaging agent for use in immuno- oncology.
AdAlta's growth strategy is to add value to its existing assets and build a pipeline of wholly owned and co-developed therapeutic products enabled by i-bodies.
About i-bodies
Traditional monoclonal antibodies transformed the pharmaceutical industry's ability to address drug targets selectively and specifically. There remain many targets and applications they have been unable to address. i-bodies are designed to solve these challenging drug targeting problems.
i-bodies are single domain antibodies that mimic the shape and stability of a unique and versatile antigen-binding domain that was discovered initially in sharks and then developed as a human protein. These unique proteins are capable of interacting with high selectivity, specificity and affinity with difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold.
About AD-214
AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases and potentially cancers, for which current therapies are sub-optimal and there is a high unmet medical need. AD-214 targets a GPCR called CXCR4 and has been specifically engineered to include features making it suitable for chronic use in fibrosis. It is the only agent against CXCR4 being developed for fibrotic diseases, giving it first-in-class status.
AD-214 has demonstrated efficacy in animal models of IPF and kidney fibrosis and studies in eye fibrosis and metastatic cancer are underway.
In Phase I clinical trials, AD-214 was well tolerated in single and multiple intravenous doses in healthy volunteers and demonstrates high and sustained duration of CXCR4 receptor occupancy. A radiolabelled version of AD-214 for safety and biodistribution (PET imaging) studies has also been developed. AdAlta is developing a more convenient inhaled formulation for future clinical studies.
AD-214 has Orphan Drug Designation (ODD) from the US Food and Drug Administration. Further information can be found at: https://adalta.com.au
For more information, please contact:
Investors
Media
Tim Oldham, CEO & Managing Director
IR Department
Tel: +61 403 446 665
Tel: +61 411 117 774
r personal use only
Corporate overview
January 2022
INVESTOR PRESENTATION - JANUARY 2022
AdAlta today
only
AdAlta is building significant growth momentum while retaining agility to respond and adapt to data and opportunities
• i-bodyplatform: can create therapeutics addressing targets underserved by traditional
antibodies
use
• Fibrosis/inflammation: lead asset AD-214preparing for Phase II clinical trial
• US$3b Idiopathic Pulmonary Fibrosis (IPF) market today,1 multiple US$b indication potential
• Second target in discovery
personalr
• Immuno-oncology: two co-development collaborations
• GZMB PET imaging agent with GE Healthcare: US$6.4b PET imaging agent market2
• i-body enabled CAR-T with Carina Biotech: US$20b market by 20283
• Continuing to build out pipeline with additional internal and external programs:
targeting 10 by 2023
• $3.75m Placement completed Dec 2021; $2.2m Entitlement Offer closes 31 Jan 2022
1.
GlobalData, Idiopathic Pulmonary Fibrosis Opportunity Analysis and Forecasts to 2029, November 2020
2.
2027 forecast by Global Industry Analysts, Imaging Agents: Global Market Trajectory and Analytics, April 2021
3.
2028 forecast by Grandview Research, "T-cell Therapy Market Size, Share & Trends Analysis" Feb 2021
INVESTOR PRESENTATION - JANUARY 2022
Four human health needs AdAlta is addressing today
only
-
Focus today
Antibodies cannot do everything!
AdAlta's i-bodies are a new drug discovery platforms for challenging targets
use
Idiopathic Pulmonary Fibrosis: degenerative, fatal
AdAlta's AD-214 could meet a desperate need for new approaches for a debilitating
disease
personalr
Immuno-oncology drugs revolutionising cancer treatment … for some
AdAlta and GE Healthcare's GZMB PET imaging could identify responders early
CAR-T cell therapy providing new hope for blood cancer patients
AdAlta and Carina's i-bodyCAR-T cells could offer same hope for patients with solid tumours
This is an excerpt of the original content. To continue reading it, access the original document here.
Disclaimer
AdAlta Limited published this content on 19 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 January 2022 21:35:13 UTC.